news17 January 2023 | By Catherine Eckford (European Pharmaceutical Review)
A marketing authorization for Ximluci® biosimilar referencing Lucentis® (ranibizumab) in Great Britain has been issued by the Medicines and Healthcare products Regulatory Agency (MHRA).